Monkey pox??? Admittedly, this term is also in the vocabulary of many since last week probably rather a “newcomer”. Admittedly, there are currently only about a handful of cases in Germany, but the WHO is sounding the alarm and the press will certainly gratefully pick up on this topic in the coming summer weeks. First contagions spread in Europe and the world.
What is the status of smallpox in your vaccination barrel?
But let’s just put the vaccination record aside, monkeypox is really bringing vaccination fun to the depots of our speculative readers right now!
The Danish company BAVARIAN NORDIC (WKN: 917165 ISIN: DK0015998017) has been ahead of the game as a supplier of an adequate smallpox vaccine for a few days now.The vaccine under the brand name Imvanex has so far been approved in Europe for use against classical smallpox.(here the link to the products)
It’s just that “first orders are coming in,” as revealed in the company’s latest press release:
BAVARIAN NORDIC SECURES VACCINE ORDER FROM EUROPEAN COUNTRY AFTER CONFIRMED MONKEYPOX CASES
(https://www.bavarian-nordic.com/investor/news/news.aspx?news=6574)
And turnover, as we all know, stimulates business, so this stock has already been in high demand since Thursday, but is still red hot!
Surely other health ministers are also already all quite pointed at calculating, or are just already inquiring about the order forms for the smallpox vaccine.
BAVARIAN NORDIC thus remains a red-hot pharmaceutical stock that could certainly add value to one or the other portfolio in the coming days and weeks.
